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use#LAAThe  progressive  accumulation  of  misfolded  proteins  in 
the brain is implicated in a vast group of human diseases, 
including  the  most  prevalent  neurodegenerative  dis­
orders  such  as  Alzheimer’s  disease  (AD),  Parkinson’s 
disease, and amyotrophic lateral sclerosis. These diseases 
are classified as protein misfolding disorders (PMDs) [1]. 
Despite  representing  an  extensive  and  active  field  of 
research,  in  most  cases  the  factors  driving  protein 
misfolding and neurodegeneration in the most common 
sporadic PMD cases remain poorly understood. Altera­
tion in protein homeostasis networks is emerging as a 
factor driving neuronal dysfunction, where disrup  tion in 
protein  quality  control  mechanisms  and  protein  clear­
ance  pathways  may  contribute  to  the  accumulation  of 
abnormally folded proteins in the brain.
The  macroautophagy  pathway  (here  referred  to  as 
autophagy) is the main degradation route for long­lived 
proteins,  damaged  organelles,  and  protein  aggregates. 
Autophagy is a highly regulated process, characterized by 
the  formation  of  double­  or  multi­membrane  vesicles 
(autophagosomes)  that  sequester  portions  of  cytosol, 
which are then delivered for degradation following fusion 
with  lysosomes  (Figure  1a).  Stimulation  of  autophagy 
results  in  the  degradation  of  most  aggregate­prone 
mutant  proteins  genetically  linked  to  PMDs  [2].  In 
addition,  the  accumulation  of  most  of  these  mutant 
proteins upregulates autophagy activity through poorly 
defined  mechanisms,  and  operates  as  a  detoxification 
mechanism.  This  suggests  that  autophagy  could  be  a 
good  target  for  disease  intervention;  however,  there  is 
accumulating  evidence  that  PMDs  involve  specific 
defects  in  particular  steps  of  the  autophagy  process. 
Thus,  manipulation  of  autophagy  in  neurodegenerative 
disease may have unpredictable outcomes, where further 
stimulation of the pathway may even overload the system 
with cargo proteins, accelerating disease.
AD  is  characterized  by  a  massive  accumulation  of 
lysosomal­related vesicles in the degenerating neurons. 
Several  studies  have  identified  specific  defects  in  the 
autophagy process in AD mouse models. For example, 
Ralph  Nixon´s  group  proposed  that  presenilin­1  (PS1) 
directly  regulates  the  acidification  of  lysosomes  by 
controlling the targeting of v­ATPase to these vesicles [3]. 
AD­linked PS1 mutations result in defective lysosomal 
proteolysis,  having  a  detrimental  impact  on  protein 
homeostasis and neuronal function [3]. In fact, genetic 
strategies  to  restore  lysosomal  function  prevented 
neuropathology and cognitive deficits of an AD mouse 
model [4]. Remarkably, restoring lysosomal function in 
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http://www.biomedcentral.com/1741-7007/10/78Figure 1. Autophagy impairment and Alzheimer´s disease. (a) Schematic representation of the general steps of the autophagy pathway. 
(b) Ablation of the essential autophagy regulator Atg7 in neurons triggers spontaneous neurodegeneration, leading to the accumulation of 
ubiquitin-positive inclusions in a p62-dependent manner. Aggregate formation also involves the recruitment of partially phosphorylated Tau and 
active GSK-3β, resembling a ‘pre-tangle’ non-amyloidogenic state. (c) Speculative model: in Alzheimer´s disease (AD), defects in the autophagy 
pathway due to genetic mutations, environmental factors and/or aging may contribute to the accumulation of abnormal protein aggregates 
and possible phospho-Tau on a pre-tangle state. For example, mutations in Presenilin-1 alter the pH of the lysosome, thus decreasing autophagy 
activity, which may enhance neurodegeneration and further accumulation of amyloid-β. Since during aging autophagy activity decreases over 
time, we speculate that autophagy impairment, together with other factors related to AD (genetic and environmental), may lead to a progressive 
flow from a pre-tangle to a neurofibrillary stage. This progression may be linked to the cognitive deficits associated with AD and tauopathies.
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amyloid­β in the brain [4], placing autophagy impairment 
as a possible upstream component in the etiology of AD.
Accumulating  evidence  suggests  that  autophagy 
activity decreases during aging, which is the major risk 
factor for developing PMDs. In agreement with this idea, 
strategies that stimulate autophagy (such as rapamycin or 
resveratrol  treatments,  and  caloric  restriction)  have 
potent anti­aging effects in vivo [2]. The first evidence 
indicating an important function of basal autophagy in 
the brain came from studies describing the effects of the 
genetic ablation of essential autophagy regulators such as 
Atg5 and Atg7 in mice [5,6]. Autophagy­deficient neurons 
undergo spontaneous degenerative changes that resemble 
those  related  to  PMD,  involving  the  accumulation  of 
ubiquitin­positive  inclusions,  neuronal  loss,  motor 
dysfunction, and premature death [5,6]. Although it was 
initially  assumed  that  the  accumulation  of  protein 
inclusions was the trigger of neurodegeneration in those 
models, an elegant study demonstrated that ablating the 
adapter  protein  p62/  SQSTM1  abrogated  the  accumu­
lation of protein aggregates in atg7 deficient neurons, but 
did  not  prevent  neuronal  dysfunction  [7].  Thus,  the 
molecular  mechanisms  explaining  the  occurrence  of 
neurodegeneration due to autophagy impairment remain 
an important open question.
In Molecular Neurodegeneration, Inoue and coworkers 
identified a surprising mechanism underlying degenera­
tion  in  autophagy­deficient  neurons,  involving  the 
engage  ment  of  a  phospho­Tau­dependent  pathway  [8]. 
Accumulation of phosphorylated Tau in neurofibrillary 
tangles represents one of the major hallmarks of AD and 
other  tauopathies,  including  frontotemporal  dementia 
[9]. The authors generated two conditional Atg7 knockout 
mice focusing on the post­natal deletion in specific brain 
areas including hippocampal and glutamatergic neurons 
within the cerebral cortex, and dopaminergic neurons in 
the midbrain (Dat-Atg7 cKO). This strategy recapitulated 
previous findings obtained with developmental inactiva­
tion of atg7 in neurons, including autophagy impairment, 
neuronal  loss,  and  accumulation  of  ubiquitin­positive 
inclu  sions. Due to increasing reports suggesting the occur­
rence  of  autophagy  impairment  in  PMDs,  the  authors 
examined  the  levels  of  the  most  common  proteins 
accumulated in these diseases. Unexpectedly, an evident 
redistribution  of  phospho­Tau  into  inclusions  was 
detected in Atg7­deficient neurons, in addition to one of 
its  kinases,  glycogen  synthase  kinase  3β  (GSK3β).  In 
contrast, no accumulation of amyloid precursor protein 
(APP), TDP­43 or α­synuclein was observed (Figure 1b) 
[8].  Interestingly,  a  recent  report  also  suggest  ed  that 
stimu  lation of mammalian target of rapamycin (mTOR)­
independent  autophagy  can  protect  neurons  against 
degeneration in mutant Tau transgenic mice due to its 
degradation of Tau aggregates [10], reinforcing the idea 
that  autophagy  also  controls  Tau  levels.  A  systematic 
characterization  of  Tau  phosphorylation  sites  in  Atg7­
deficient neurons indicated that the pattern observed was 
similar to an early ‘pre­tangle’ state that does not lead to 
formation  of  amyloid  or  fibrillar  structures.  Using  a 
pharmacological approach to inhibit Tau phosphorylation 
or  the  genetic  ablation  of  tau  in  mice,  the  authors 
partially reverted the neurodegenerative effects of Atg7 
deficiency. Remarkably, the formation of ubiquitin/p62­
positive inclusions remained intact after these manipu­
lations, suggesting that Tau­mediated neurodegenera  tion 
may  represent  (i)  a  downstream  pathological  event  of 
abnormal  protein  aggregation,  or  (ii)  a  parallel  pheno­
menon triggered by an unknown mechanism. It will be 
interesting  to  determine  if  deletion  of  p62  in  Atg7 
knockout  mice  affects  Tau/GSK3β  redistribution  and 
phosphorylation.
This  study  suggests  for  the  first  time  a  connection 
between  autophagy  impairment,  Tau  pathology,  and 
neurodegeneration (Figure 1c), and given the emerging 
association  between  autophagy  dysfunction  and  aging, 
provides  clues  about  the  possible  cause  of  the  most 
common sporadic forms of neurodegenerative diseases, 
offering an interesting possibility for future therapeutic 
intervention.
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